Core Insights - BioNTech will present data on its lung cancer portfolio at the European Lung Cancer Congress (ELCC) from March 25-28, 2026, highlighting advancements in late-stage immunomodulators and antibody-drug conjugates [1][2] Group 1: Lung Cancer Programs - Pumitamig (BNT327/BMS986545) is a bispecific immunomodulator candidate that combines PD-L1 checkpoint inhibition and VEGF-A neutralization, developed in collaboration with Bristol Myers Squibb [3] - Gotistobart (BNT316/ONC-392) targets CTLA-4 and is designed for tumor microenvironment-selective regulatory T cell depletion, developed in collaboration with OncoC4 [3] - In the Phase 3 PRESERVE-003 trial, gotistobart demonstrated a 54% reduction in the risk of death compared to standard chemotherapy in patients with squamous non-small cell lung cancer (NSCLC) who had progressed on prior treatments [3][4] Group 2: Clinical Trial Updates - Updated data from a Phase 2 trial in China showed promising antitumor activity for pumitamig combined with chemotherapy as first-line therapy in extensive-stage small cell lung cancer (ES-SCLC) [5] - New findings from a Phase 1b/2a trial indicated preliminary antitumor activity for pumitamig as a first-line monotherapy in advanced NSCLC, regardless of PD-L1 expression levels [5] - Data from a Phase 2 trial showed significant survival outcomes for pumitamig combined with chemotherapy in patients with EGFR-mutant advanced NSCLC, highlighting its potential for those progressing on EGFR inhibitors [5] Group 3: HER3-targeted ADC - BNT326/YL202 is a HER3-targeted ADC candidate that has shown antitumor activity and a favorable safety profile in advanced or metastatic NSCLC patients who progressed after standard therapy [6] - The ongoing Phase 1b/2 trial is evaluating the combination of pumitamig and BNT326/YL202, further expanding BioNTech's lung cancer treatment options [6] Group 4: Overall Strategy - BioNTech is advancing a diversified clinical development approach in lung cancer, with 16 ongoing clinical trials across various subtypes and treatment lines, including four pivotal Phase 3 trials [6] - The company aims to address significant unmet medical needs in lung cancer treatment through innovative therapies, including next-generation immunomodulators and antibody-drug conjugates [6]

Core Insights - Bristol Myers Squibb (BMY) has a robust pipeline with several candidates that have multi-billion-dollar potential, including milvexian, admilparant, pumitamig, iberdomide, and mezigdomide [1] Pipeline Developments - BMY anticipates reporting top-line registrational data for six candidates in 2026, including milvexian for atrial fibrillation and secondary stroke prevention, admilparant for idiopathic pulmonary fibrosis, and iberdomide for relapsed or refractory multiple myeloma [2] - Positive interim results from the SUCCESSOR-2 study were announced, showing the efficacy and safety of mezigdomide in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma [3][4] - Milvexian is being developed in partnership with Johnson & Johnson for atrial fibrillation and secondary stroke prevention, potentially redefining anticoagulant therapy [5] - Admilparant is under evaluation for idiopathic pulmonary fibrosis, with data from the ALOFT-IPF study expected later this year [6] - Pumitamig, a bispecific antibody, is being developed with BioNTech for various solid tumor types, with initial data expected later this year [7] Label Expansion and New Indications - BMY is expanding the label of its approved drug Sotyktu (deucravacitinib) to include treatment for adults with active psoriatic arthritis, and it is also being evaluated for lupus and Sjogren's Disease [8] - The schizophrenia drug Cobenfy is being assessed for its efficacy in treating psychosis associated with Alzheimer's disease [9] Competitive Landscape - BMY's growth portfolio includes several key drugs such as Opdivo, Orencia, and Yervoy, but it faces competition from major pharmaceutical companies like Merck and Pfizer in the oncology space [10][12] - Merck's Keytruda dominates the immuno-oncology market, accounting for approximately 50% of its pharmaceutical sales [13] Financial Performance and Valuation - BMY's shares have decreased by 0.5% over the past year, contrasting with the industry's growth of 16.6% [19] - The company is trading at a price/earnings ratio of 9.64x forward earnings, which is lower than the large-cap pharma industry's average of 17.99x [20] - The Zacks Consensus Estimate for BMY's 2026 EPS has increased to $6.26 from $6.15 over the past 30 days, indicating positive revisions [21]

Core Insights - The co-founders of BioNTech, Uğur Şahin and Özlem Türeci, will leave the company to establish a new mRNA-focused entity by the end of 2026, amid increasing losses for BioNTech [1][2] - BioNTech's Q4 2025 revenue fell to €907.4 million ($1.05 billion), a 25% decrease from €1.2 billion in 2024, while net losses surged 57% to €1.1 billion in 2025 compared to €665.3 million the previous year [3] - BioNTech is shifting its focus towards oncology, with over 25 Phase II and III programs in development, aiming to become a fully integrated multiproduct oncology company [6] Company Developments - The new company led by Şahin and Türeci will have separate resources and operations, with BioNTech contributing certain mRNA technologies to expedite the development of new candidates [2] - BioNTech's share price has declined over 75% from its mid-2021 highs as demand for COVID treatments has decreased [5] - The company has partnered with Bristol Myers Squibb (BMS) for the development of pumitamig, a cancer drug in late-stage trials, with potential revenues exceeding €2 billion by 2032 [7] Strategic Focus - BioNTech is targeting oncology to enhance its financial performance, with a pipeline that includes next-generation immunomodulators, antibody-drug conjugates (ADCs), and mRNA cancer immunotherapies [6] - The acquisition of German rival CureVac for $1.25 billion last year has expanded BioNTech's cancer immunotherapy pipeline [7]

Crescent Biopharma Conference Call Summary Company Overview - **Company**: Crescent Biopharma - **Focus**: Development of next-generation oncology therapies, particularly in immuno-oncology (IO) and antibody-drug conjugates (ADCs) targeting various cancers including thoracic, gynecological, gastrointestinal, and head and neck cancers [4][5] Key Assets and Strategies - **CR-001**: A PD-1 VEGF bispecific antibody positioned as a potential best-in-class therapy and a backbone for next-generation IO treatments [4][6] - **ADC Portfolio**: Includes CR-002 (PD-L1 Topo ADC), CR-003 (integrin beta-6 Topo ADC), and CR-004 (undisclosed target ADC). The strategy involves novel combinations of CR-001 with ADCs [5][6] - **Partnership with Kelun-Biotech**: Involves in-licensing of integrin beta-6 Topo ADC for territories outside Greater China and collaboration on CR-001 in Greater China [5][16] Market Opportunity - **Market Size**: The oncology market for PD-1 VEGF therapies is estimated to exceed $100 billion, with significant opportunities for first-in-class therapies outside of China [6][7] - **Indications**: There are 40-50+ potential indications for PD-1 VEGFs in solid tumors, with most lacking late-stage trials outside of China [6] Clinical Development Plans - **Clinical Trials**: Crescent plans to initiate more clinical trials in 2026, with multiple readouts expected in Q1 2027. The company is well-funded through 2028 following a capital raise [7][8] - **Data Generation**: The partnership with Kelun allows for parallel data generation in both the U.S. and China, enhancing the efficiency of clinical development [72] Competitive Landscape - **Integrin Beta-6 ADC**: The most advanced competitor is Pfizer's integrin beta-6 ADC, currently in phase 3 trials. Crescent believes its asset has superior safety and efficacy profiles due to optimized payload and linker technology [41][46] - **Differentiation**: Crescent's CR-001 is designed to avoid common side effects associated with other therapies, such as neuropathy, and aims to provide a better therapeutic index [42][46] Mechanistic Insights - **Cooperative Pharmacology**: The mechanism behind CR-001's efficacy involves cooperative pharmacology, which enhances the PD-1 signal while reducing adverse events associated with VEGF inhibitors [51][52] - **Comparison with Other Agents**: Crescent's CR-001 is designed to be comparable to ivonescimab, with a focus on maintaining functionality while improving stability and safety [62][64] Future Directions - **Combination Strategies**: Crescent is exploring combinations of CR-001 with both ADCs and traditional chemotherapy, aiming to create a robust pipeline of anti-tumor agents [73] - **PD-L1 ADC Development**: The company is also developing a PD-L1 ADC with a focus on optimizing binding affinity and internalization capabilities to differentiate from competitors [75][76] Conclusion Crescent Biopharma is strategically positioned in the oncology market with a focus on innovative therapies and partnerships that enhance its clinical development capabilities. The company aims to leverage its differentiated assets and collaborative efforts to capture significant market opportunities in the evolving landscape of cancer treatment [6][7][8]

Core Insights - BioNTech's stock is experiencing a significant decline, with shares down 17.67% to $84.11, reflecting investor concerns over the company's future direction and revenue outlook [8]. Revenue Outlook - The company has guided total revenue for 2026 to be approximately $2.2–$2.5 billion, which is below market expectations, indicating that Covid-19 will contribute less to revenue moving forward, with growth increasingly reliant on the oncology pipeline [2]. COVID-19 Business Performance - CFO Ramon Zapata stated that while the company maintains a strong market share and stable pricing for COVID-19, it has anticipated lower volumes compared to the previous year, framing current performance as aligned with expectations rather than a return to pandemic-era profits [3]. Oncology Strategy - BioNTech is pivoting towards its oncology portfolio, with CEO Sahin emphasizing the transformation of scientific advances into late-stage programs across various indications, indicating a multi-year investment phase before substantial revenue contributions from oncology [4]. Financial Position - The company reassured investors about its balance sheet strength, reporting over EUR 16 billion (approximately $17.2 billion) in cash, equivalents, and securities, which will support planned R&D spending in the range of $2.4–2.7 billion for cancer immunotherapies [5][6]. Leadership Concerns - The recent departure of key leaders Sahin and Tureci has raised concerns about leadership continuity and the potential impact on the company's scientific and strategic capabilities, contributing to investor unease alongside the softer revenue outlook and increased R&D investment [7].

Financial Data and Key Metrics Changes - Total revenues for 2025 were EUR 2.9 billion, a slight increase from the prior year despite a decrease in COVID-19 vaccine revenues [27] - The company ended 2025 with EUR 17.2 billion in cash equivalents and security investments, positioning it strongly for future investments [28] - Adjusted non-IFRS net loss for 2025 was EUR 117 million [29] Business Line Data and Key Metrics Changes - The company maintained over 50% market share in major markets for its COVID vaccine, distributed in over 180 countries [6] - R&D expenses were approximately EUR 2.1 billion, slightly decreased from the prior year, aided by cost savings from active portfolio management [27] - The oncology programs advanced significantly, with over 4,000 patients enrolled across phase 2 and phase 3 studies [6][8] Market Data and Key Metrics Changes - The company anticipates lower COVID-19 vaccine revenues in 2026 due to declining demand in both the U.S. and European markets [30][31] - The U.S. market is expected to be particularly competitive, impacting revenue generation [30] Company Strategy and Development Direction - The company aims to transition to a tumor-centric clinical development program focused on high-incidence cancers, including lung and breast cancer [8] - A new independent company will be established to pursue next-generation mRNA innovations, with BioNTech retaining a minority stake [10][11] - The strategic focus will remain on late-stage oncology assets and combination therapies to maximize value [11][33] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to execute its strategy and achieve significant clinical data output from 2026 to 2029 [33] - The transition to a new leadership structure is planned for the end of 2026, aligning with key milestones and data readouts [49][50] Other Important Information - The company has established a partnership with BMS to strengthen its oncology programs and de-risk its pumitamig initiatives [6][8] - The company is preparing for multiple late-stage data readouts in 2026, which are expected to inform pivotal trials [8][25] Q&A Session Summary Question: How will the mRNA therapeutics be split between BioNTech and the new company? - Management confirmed that all current mRNA capabilities will remain with BioNTech, while the new company will focus on next-generation innovations [37][40] Question: What is the profile for the new CEO search? - The supervisory board is looking for leaders with strong experience in late-stage development and commercial execution [44][46] Question: Why is the leadership transition happening now? - The transition is planned for the end of 2026, coinciding with significant data readouts and the need for industrialization [49][50] Question: Will BioNTech contribute capital to the new company? - BioNTech will not contribute cash but will transfer certain rights and mRNA technologies [54][55] Question: What are the expectations for COVID-19 vaccine revenues in 2026? - Lower revenues are anticipated due to market normalization and seasonal demand [95][96]

Financial Data and Key Metrics Changes - Total revenues for 2025 were EUR 2.9 billion, a slight increase from the prior year, despite a decrease in COVID-19 vaccine revenues [27] - R&D expenses were approximately EUR 2.1 billion, a slight decrease from the prior year, enabled by cost savings and positive effects from cost-sharing with BMS [27] - The company ended 2025 with EUR 17.2 billion in cash equivalents and security investments, positioning it strongly for future investments [28] - An adjusted non-IFRS net loss of EUR 117 million was reported for 2025 [29] Business Line Data and Key Metrics Changes - The company maintained over 50% market share in the COVID vaccine market, distributing its vaccine in over 180 countries [6] - Significant progress was made in oncology programs, with over 4,000 patients enrolled across phase II and phase III studies [6] - The company executed strategic deals, including acquiring Biotheus and CureVac, to strengthen its oncology pipeline [7] Market Data and Key Metrics Changes - The company anticipates lower COVID-19 vaccine revenues in 2026 compared to 2025, driven by declines in both European and U.S. markets [30] - The U.S. market is expected to be competitive and dynamic, impacting revenue generation [30] - In Germany, direct sales of COVID-19 vaccines will significantly affect the company's top line [31] Company Strategy and Development Direction - The company aims to become a multi-product company by 2030, focusing on oncology and personalized medicine [10] - Key priorities for 2026 include accelerating late-stage development of oncology assets, building momentum in combination-based approaches, and evolving to a tumor-centric clinical development program [8] - The company plans to leverage its diverse clinical assets for combination strategies to address multiple lines of treatment [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong financial position and disciplined resource allocation, focusing on late-stage programs [8] - The transition to a new independent company for next-generation mRNA innovations is expected to enhance BioNTech's strategic focus [10] - Management anticipates a sustained cadence of event-driven late-stage readouts from 2026 to 2030, with significant potential to improve patient outcomes [9] Other Important Information - The company will supplement its IFRS reporting with adjusted non-IFRS measures to provide better context for business performance [28] - A binding agreement for the new company is expected to be signed by the end of the first half of 2026 [11] Q&A Session Summary Question: How will the mRNA therapeutics be split between BioNTech and the new company? - Management confirmed that all current mRNA capabilities will remain with BioNTech, while the new company will focus on next-generation innovations [38][40] Question: What is the profile for the new CEO search? - The supervisory board is looking for leaders with strong experience in late-stage development and commercial execution [46] Question: Why is the management transition happening now? - The transition is planned for the end of 2026, aligning with key milestones and data readouts [49][50] Question: Will BioNTech contribute capital to the new company? - BioNTech's contribution will relate to certain rights and mRNA technologies, not cash [54] Question: What are the expectations for COVID-19 vaccine revenues in 2026? - Lower revenues are anticipated due to market normalization and seasonal demand [95]

4 th Quarter & Full Year 2025 Financial Results & Corporate Update March 10th, 2026 This Slide Presentation Includes Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: expected changes to BioNTech's leadership and the transition of responsibilities at the Management Board; preliminary discussions between BioNTech and the co-founders regar ...

Investment Rating - The report does not explicitly state an investment rating for the industry Core Insights - The proportion of driver gene-negative non-small cell lung cancer (NSCLC) patients is approximately 31% in both China and the United States, indicating a significant market opportunity for treatments targeting this demographic [2][15] - The estimated market size for immune drugs used in first-line treatment of driver gene-negative NSCLC is projected to be around 7.5 billion CNY (approximately 1.1 billion USD) in China and 18 billion CNY (approximately 2.7 billion USD) in the United States by 2030 [2] - The current first-line treatment for advanced driver gene-negative NSCLC primarily relies on PD(L)-1 inhibitors combined with chemotherapy, but there are limitations in long-term efficacy and options for patients intolerant to chemotherapy [3] Summary by Sections Section 1: NSCLC Global Overview - Lung cancer is the leading cancer type globally, with new cases accounting for approximately 12% of all cancer cases in 2022, translating to about 2.5 million new lung cancer cases [10] - In China, lung cancer represents about 22% of new cancer cases, with approximately 1.06 million new cases in 2022 [10] Section 2: Market Potential for Driver Gene-Negative NSCLC - The report highlights the significant market potential for immune therapies in treating driver gene-negative NSCLC, with a focus on the limitations of current treatment options [2][3] Section 3: Next-Generation Immunotherapy Approaches - The report discusses the advancements in dual (multi) antibody therapies and immune-oncology (IO) combined with antibody-drug conjugates (ADC), emphasizing their potential to improve treatment outcomes for patients with driver gene-negative NSCLC [5][8] - The clinical data supporting these new therapies is expected to catalyze further investment and development in this area [5] Section 4: Treatment Guidelines Comparison - The report compares treatment guidelines for driver gene-negative NSCLC between the United States and China, noting differences in treatment stratification and recommended therapies [32][34] - The U.S. guidelines emphasize PD-L1 expression levels, while Chinese guidelines focus more on performance status (PS) [32][34] Section 5: Future Catalysts - Key upcoming clinical data releases and studies are highlighted as potential catalysts for investment opportunities in the sector, particularly regarding dual antibodies and ADC therapies [5][8]

Investment Rating - The industry investment rating is "stronger than the market" indicating an expected performance that exceeds the market by more than 5% over the next six months [32]. Core Insights - Eli Lilly's total revenue for 2025 is projected to reach $65.179 billion, representing a significant year-on-year growth of 45%. The revenue for 2026 is expected to be between $80 billion and $83 billion. The two key products, Tirzepatide, are anticipated to contribute a combined global sales of $36.5 billion, with the diabetes version Mounjaro generating $22.965 billion (up 99% year-on-year) and the weight loss version Zepbound achieving $13.542 billion (up 175% year-on-year) [3]. - Eli Lilly's drug approval progress for 2025 includes the FDA approval of the multi-dose prefilled pen for Tirzepatide and the approval of a new indication for the drug Jaypirca. Applications for obesity indications of Orforglipron have been submitted to U.S. and Japanese regulatory agencies, along with submissions to the EU for both obesity and type 2 diabetes indications [3]. - The pipeline progress for Eli Lilly in 2025 includes positive results from Phase 3 clinical trials for the combination of Taltz and Tirzepatide in adult patients with active psoriatic arthritis and obesity. Orforglipron has shown positive clinical results in studies transitioning from injectable to oral incretin therapy, and Retatrutide has also shown positive results in studies involving obesity with knee osteoarthritis [3]. Summary by Sections Industry Overview - The biopharmaceutical industry is rated as stronger than the market, maintaining a positive outlook [3][4]. - The investment strategy emphasizes the increasing global competitiveness of Chinese innovative pharmaceutical companies, focusing on potential therapeutic areas such as metabolic diseases, chronic diseases, and central nervous system disorders [4]. Market Performance - The pharmaceutical sector saw a slight increase of 0.14% last week, while the Shanghai and Shenzhen 300 Index decreased by 1.33%. The pharmaceutical industry ranked 14th among 28 industries in terms of performance [8][18]. - The valuation of the pharmaceutical sector is currently at 29.57 times (TTM), with a premium of 10.50% over the overall A-shares excluding financials [23]. Notable Company Developments - Cloudtop announced the approval of Velsipity® for treating moderate to severe ulcerative colitis in China, marking a significant advancement in treatment options [12]. - BMS reported a total revenue of $48.194 billion for 2025, with the drug Opdivo generating $10.049 billion, reflecting an 8% increase [13]. - Innovent Biologics achieved a total product revenue of approximately 11.9 billion yuan for 2025, maintaining a strong growth rate of about 45% [15]. - Saintin Biotech announced a strategic collaboration with Genentech for RNAi drug development, highlighting ongoing innovation in the sector [16].